logo
Prices are 'elevated' & 'significant risks' remain: Jamie Dimon

Prices are 'elevated' & 'significant risks' remain: Jamie Dimon

Yahoo6 days ago
JPMorgan (JPM) released second quarter earnings results on Tuesday. On the earnings call, JPMorgan CEO Jamie Dimon said that asset prices are elevated and present a risk to the market going forward.
New York Life Investments economist and portfolio strategist Lauren Goodwin joins Opening Bid host Brian Sozzi to share her thoughts on Dimon's comments, and Yahoo Finance Senior Reporter Allie Canal provides additional context, including the latest inflation data, the state of the US economy, and the Federal Reserve's upcoming meeting.
To watch more expert insights and analysis on the latest market action, check out more Opening Bid here.
One thing that Jamie Dimon, uh, said on his prepared remarks on earnings releases that stood out to me. He thought or he thinks, uh, asset prices are elevated and then secondarily that is a risk moving forward. Do you agree with him?
I do agree with him. It's not necessarily that asset prices are unfair for the economic backdrop that we have today, but we know that there are risks on on the horizon that are likely to impact the economic data and reality moving forward. Now, from a high-level markets and macroeconomic perspective, the earnings reports that we have coming out this quarter are likely to be reasonable. And I don't expect that the worst of the policy risks that we're seeing unfold in the moment to really hit the economic data until later this quarter and into Q4. And so, we're looking at a market environment that could continue to be constructive moving forward. But as investors, we have to think very carefully about where incremental sources of value are. If they've been stored in momentum and beta here in the last couple of months, then focusing on the fundamentals and credit quality becomes so much more important moving forward.
Lord, let me just follow up on that because is this one of those calls from from Jamie Dimon where we we appreciate today, but a week from now the markets are off their highs and we go back and think, well, Jamie Diamond called the market top. Is that what do you think he's trying to say here?
You know, I think that the the the banks in particular have many policy backdrop components that they've been benefiting from and may continue to benefit from moving forward. Last year the Fed cut rates by 100 basis points that helps deepen the curve that tends to be, uh, tends to be constructive for bank earnings. More volatility means more sales and trading revenue, which can, uh, bolster bank earnings as well. And we're looking at a deregulatory backdrop moving forward that might be more favorable to the banks. I think the real challenge is if we see demand destruction as a result of tariffs or other policy changes moving forward. That's really where the challenge for the banks comes ahead. And so, if nothing else, I see this as a a way to hedge the the elements of the economic backdrop that, uh, CEO can't control right now.
I asked Jamie Diamond on a call with, uh, with reporters this morning why he called out elevated risks or elevated asset prices as a risk. I mean he kind of laughed at me a little bit, he giggled. He's well, he basically said, well, look at the alternative would be stocks would be down. But he did bring up a good point in that the market is pricing in a soft landing. And I thought that was a very good thing to call out.
Yeah, and if you even take a look at the inflation data, right, we have yet to see those tariffs really affect consumer prices. We did see a little bit of signs apparel prices ticking up, footwear ticking up. But used cars, new vehicles, those prices dropped. And that's an encouraging sign at where we're at. Now, at the same time, economists have been saying we saw a lot of front loading. Tariffs are going to take time to work their way through the system. So it'll be interesting to see how investors react to that. But then earlier this morning, we saw Bank of America release its fund manager survey and it did say that sentiment was getting toppy, but that equity positioning is not yet extreme, even though it's overweight. So that is a positive sign moving forward that perhaps this rally can continue, perhaps we can achieve the soft landing. Of course, Brian, as we know, the big TBD factor there is the Federal Reserve. What they decide to do when it comes to interest rates and the CPI report that we got this morning, pretty much tells us story that the Fed is going to remain on hold for the foreseeable future. We have markets pricing in basically a 100% chance that the Fed remains on hold in the next two weeks when we get that policy decision. And then September we also saw odds dip below 60%. And that's pretty notable here since markets had consistently been pricing in a September rate cut. But it seems like markets are now thinking, maybe we could see a cut in December or maybe not even at all this year. And I wonder how investors will react to that reality.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug
Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Yahoo

time44 minutes ago

  • Yahoo

Sarepta Therapeutics stock sinks after FDA tells company to stop shipping its bestselling drug

Sarepta Therapeutics' (SRPT) stock continued to sink Monday, down more than 8% in early trade though quickly paring losses following a rough end to last week, including a previously unreported patient death in a clinical trial of an unnamed therapy and the threat of the FDA taking a different therapy, Elevidys, off the market. Both therapies aim to treat different types of muscular dystrophy. This extended decline in the stock comes even as analysts have pared back their concerns over the weekend, after Wall Street sent the stock into free fall on Friday, down 35% at the close of trading. "Net-net, so long as Elevidys stays on the market (which we think, post digging into FDA's press release on Friday, is certainly the case for ambulatory patients), from current levels, there is upside in SRPT shares. We acknowledge that if we are wrong about Elevidys staying on the market in ambulatory patients, fundamentally, then this would clearly be thesis changing for us," JPMorgan analyst Anupam Rama wrote in a note to clients Monday. Elevidys generated $282 million in revenues in the second quarter of this year, or about half of the company's $513 million in net revenues. The patient death occurred a month ago in a phase 1 trial of the unnamed therapy but was not revealed in an earnings call last week. BioCentury first reported the patient death, which then prompted the FDA to request Sarepta to halt shipments of Elevidys, its Duchenne muscular dystrophy drug. Sarepta refused. That shocked analysts who on Friday and Saturday said that management's handling of the situation, as well as its defiance of the FDA, has put investors in "unprecedented times." "This saga continues to get messier, and we are increasingly in unprecedented times, with the FDA requesting Sarepta to suspend the distribution of Elevidys, and the company refusing to do so," Leerink Partners analyst Joseph Schwartz wrote in a note to clients Saturday. Elevydis was also in the crosshairs after two teenagers died earlier this year following treatment, making the latest death the third for the company in a year. Leerink downgraded the stock to Market Perform and lowered its price target to $10 from $14. The company's stock is down 88% year to date. Read more about Sarepta's stock moves and today's market action. Management's messaging The downturn began just days after Sarepta's second quarter earnings call, in which CEO Doug Ingram said the company would end several clinical trials, including for SRP-9004, as part of a restructuring. But none of the executives on the call mentioned the death. On a call with investors Friday, Ingram attempted to quell concerns that ending some research programs was related to the death and was focused instead on the need to cut costs. "We did not discuss this matter in our call on Wednesday, because it was neither material nor central to the topics at hand on Wednesday," Ingram said at the start of the call Friday. He described the patient as a 51-year-old late-stage, nonambulatory male. "After only recently learning about a death that occurred a month ago ... [we are] losing any remaining confidence we had in the management team, and seeing the headlines that the FDA will request SRPT to voluntarily stop all shipments of Elevidys (SRP-9001) in Duchenne muscular dystrophy (DMD), we stepped to the sidelines and downgraded the stock," Leerink's Schwartz wrote in a note to clients Friday. Jefferies analyst Andrew Tsai said the revelation could make Sarepta's stock less appealing. "Seeing a third SRPT-related death occur within a span of 4 months will raise questions about SRPT's gene therapy platform," Tsai wrote on Friday. "Serious downside risks (i.e. deaths) have been challenging to handicap, which could cause near-term stock exhaustion." In a statement Friday, following the FDA's request to halt Elevidys, Sarepta said it did not see a reason to acquiesce. "Based on our comprehensive scientific interpretation of the data, which shows no new or changed safety signals in the ambulant patient population, we will continue to ship Elevidys to the ambulant population. We look forward to continued discussions and sharing of information with FDA in order to advance our shared purpose of protecting patient safety and informed access to care," the company said in a statement Friday. Weekend turnaround Over the weekend, management spoke with analysts and appeared to have allayed some concerns. They told analysts that the FDA was aware of the death and that the agency's sudden request to pull Elevidys was not valid. "Regarding the FDA's request that SRPT voluntarily stop all shipments of Elevidys (SRP-9001) in Duchenne muscular dystrophy (DMD), management agreed with our thoughts that this was seemingly in reaction to the headlines on Friday, rather than a decision rooted in science or regulatory precedent, especially as the agency has been aware of the death ... for quite some time," Leerink's Schwartz wrote. Others, like JPMorgan's Rama, noted that the FDA is unlikely to pull the drug off the market for the population unaffected by the drug — the mobile, or ambulatory, population. Meanwhile, Jefferies analyst Andrew Tsai held a more cautious tone. "We acknowledge the story could be challenging to navigate after a third patient death, but we are merely assessing the situation as more information becomes available," he wrote in a note to clients on Sunday. "Despite the FDA's request to halt Elevidys shipments, SRPT will elect to continue shipping the gene therapy to ambulatory DMD patients. Since we are unsure if the FDA can pull Elevidys, the logical question is how Elevidys sales will trend amid increased uncertainty and pot'l FDA controversy." Sarepta's management also told analysts that if it were forced to pull Elevidys, it would have to cut more costs in order to stay afloat. Anjalee Khemlani is the senior health reporter at Yahoo Finance, covering all things pharma, insurance, provider services, digital health, PBMs, and health policy and politics. That includes GLP-1s, of course. Follow Anjalee as AnjKhem on social media platforms X, LinkedIn, and Bluesky @AnjKhem. Click here for in-depth analysis of the latest health industry news and events impacting stock prices

United Parcel Service, Inc. (UPS) Launches Voluntary Separation Program; JP Morgan Maintains ‘Neutral' Rating
United Parcel Service, Inc. (UPS) Launches Voluntary Separation Program; JP Morgan Maintains ‘Neutral' Rating

Yahoo

time3 hours ago

  • Yahoo

United Parcel Service, Inc. (UPS) Launches Voluntary Separation Program; JP Morgan Maintains ‘Neutral' Rating

With a low P/E multiple and potential upside for investors, United Parcel Service, Inc. (NYSE:UPS) is among the . Copyright: lightpoet / 123RF Stock Photo On July 8, 2025, JPMorgan decreased its price target on United Parcel Service, Inc. (NYSE:UPS) from $110 to $107, maintaining a 'Neutral' rating. The analysts at the firm cited persisting uncertainty regarding tariffs and trade policy, and the volatility of spot truckload rates. Meanwhile, on July 18, 2025, under its largest network reconfiguration to date, United Parcel Service, Inc. (NYSE:UPS) launched a voluntary separation program for its full-time employees. Under this program, eligible drivers will earn $1,800 per year of service, in addition to their earned retirement benefits like insurance and health. The employees will earn a minimum payout of $10,000. United Parcel Service, Inc. (NYSE:UPS) has over 10,000 drivers with 25+ years of experience. Thus, this program aims to support such long-serving employees, along with helping the company adapt to rapidly changing business demands. United Parcel Service, Inc. (NYSE:UPS), offering package delivery and logistics services, operates through two segments, U.S. Domestic Package and International Package. It is on the list of cheap transportation stocks. While we acknowledge the potential of UPS as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 7 Best Stocks to Invest in for a Quick Return and 10 Best Cheap Stocks to Buy According to Billionaire Ray Dalio. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store